Methods: This is a sub study of the all-comers EXAMINATION Trial that randomized 1498 patients with STEMI undergoing percutaneous coronary intervention (PCI) to EES or BMS. For the purpose of this substudy, the patient-oriented combined endpoint of all-cause death, any recurrent myocardial infarction and any revascularization, target lesion revascularization and stent thrombosis rates were analyzed according to the gender at 2-year follow-up. Results: Out of 1498 patients included in the trial, 254 (17.0%) women were included and randomized to BMS (n¼137, 53.9%) or EES (n¼117, 46.1%). Women were older (67.9 vs. 59.8; p<0.01), had higher prevalence of hypertension (62.2% vs. 45.6%; p<0.01) and a lower prevalence of smoking (36.6% vs. 79.5%; p<0.01) as compared with men. Also women had a lower use of thrombectomy (59.1% vs. 66.4%; p¼0.02) and IIb/IIIa inhibitor than men (44.9% vs. 53.9%, p<0.01). In contrast with men, stent diameter was smaller in women (3.07 mm vs. 3.23 mm, p<0.01). Compliance of dual antiplatelet therapy at one year was lower in women than in men. After adjustment per confounders, the primary endpoint was similar between men and women (HR 0.95; 95%CI 0.66-1.37) and within women, between those treated with BMS versus EES (HR 1.54: 95%CI 0.77-3.11). Women showed a lower rate of repeat revascularization than men (HR 0.55; 95%CI 0.32-0.95) despite worse baseline characteristics. The difference was driven by an outperformance of EES in women. No differences in definitive/probable stent thrombosis (1.2% vs. 2.0% HR 0.58; 95%CI 0.17-1.94) was observed between women and men. Conclusions: Our substudy may suggest that EES would have a more potent antiproliferative effect in women suffering from STEMI as compared to men without any safety concerns.
Background: Intraprocedural thrombotic events (IPTE) during percutaneous coronary intervention (PCI) are associated with adverse outcomes in patients with both non-STsegment elevation and ST-segment elevation acute coronary syndromes (NSTEACS/ STEMI). We have previously validated the occurrence of IPTE to be a powerful independent predictor of early and late major adverse cardiac events (MACE) after PCI. The extent to which individual components of IPTE are associated with adverse events is unknown. Methods: A total of 6,591 patients who received PCI for NSTEACS/STEMI in the Acute Catheterization and Urgent Intervention Triage StrategY (ACUITY) and Harmonizing Outcomes with RevascularIZatiON and Stents in Acute Myocardial Infarction (HORIZONS-AMI) trials underwent detailed frame-by-frame core laboratory angiographic analysis to assess for IPTE. IPTE was defined as the occurrence of new/worsened thrombus, abrupt closure, no reflow/slow flow, distal embolization, or intraprocedural stent thrombosis (IPST). The independent associations of IPTE components with death, major bleeding, and MACE at 30-days were assessed using multivariable models. Results: The overall incidence of IPTE was 7.8%. Among patients with IPTE, no reflow/slow reflow was present in 58.0%, new/worsened thrombus in 35.3%, distal embolization in 34.9%, abrupt closure in 19.8%, and IPST in 9.5% of patients. Each IPTE component was associated with 30-day death, major bleeding, and MACE in multivariable models (Table) , with the strongest association observed for IPST.
Conclusions:
The occurrence of IPTE is not infrequent among high-risk ACS patients undergoing PCI. The single component with the strongest association with adverse events was IPST, which fortunately represented <10% of IPTE events overall. Future therapeutic strategies aimed at minimizing the occurrence and consequences of IPTE are warranted. Background: While acquired TP has consistently been associated with short-and long-term adverse outcomes after PCI, the impact of baseline TP, however, has not been as thoroughly investigated. Methods: Data from 10,569 pts presenting with NSTEACS or STEMI in whom PCI was performed was pooled from 2 large-scale randomized trials, ACUITY and HORIZONS. Outcomes were examined according to the presence of baseline TP, defined as platelet counts <150 X 103/mm3. Results: Baseline TP was present in 573 (5.4%) pts. Patients with baseline TP were more likely to have diabetes, hypertension, hyperlipidemia, renal dysfunction and prior PCI and greater number of lesions and diseased vessels. The unadjusted 1-year rate of death (6.7% vs. 3.6%, p<0.0001), MACE (21.3% vs.15.6%, p<0.0001), target vessel revascularization (11.1% vs. 8.5%, p¼0.01) and target lesion revascularization (TLR; 9.6% vs. 7.2%, p¼0.01) was significantly higher in pts with baseline TP compared with pts with no TP. By multivariable analysis, the presence of TP at baseline was an independent predictor of Background: Women are at high risk for mortality after ST-elevation acute myocardial infarction (STEMI). Whether sex-disparities still exist in the treatment and mortality of patients after STEMI remains controversial. The aim of this study was to assess recent trends in hospital mortality and in treatment modalities for patients with STEMI according to sex. 
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